Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Patients With Primary or Recurrent Pterygium

Trial Profile

A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Patients With Primary or Recurrent Pterygium

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Pterygium
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cloudbreak Pharma

Most Recent Events

  • 22 Apr 2026 According to Cludbreak media release, the data from the trial will be presented at Eyecelerator (partnership between ASCRS (American Society of Cataract and Refractive Surgery) and the American Academy of Ophthalmology) at the ARVO 2026.
  • 01 Sep 2018 Status changed from active, no longer recruiting to completed.
  • 17 Jul 2018 Planned primary completion date changed from 26 May 2018 to 30 Sep 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top